The DOI matches its Crossref record.
Prevention of Amphotericin B—Induced Renal Impairment: A Review on the Use of Sodium Supplementation
Abstract
• Amphotericin B is the treatment of choice for most deepseated mycoses; however, doses may have to be limited because of concern over adverse effects such as nephrotoxicity. Evolving evidence suggests that the extent of amphotericin B—induced renal impairment may be modified via alteration of a normal physiologic feedback response that further contributes to changes due to direct nephrotoxicity. As such, renal impairment has a substantial theoretically preventable and reversible element. In animals exposed to amphotericin B, sodium loading interferes with this response. Mounting clinical evidence also supports the usefulness of sodium supplementation to prevent as well as to reverse amphotericin B—induced nephrotoxicity. At this time, the use of sodium supplementation (eg, intravenous saline and/or ticarcillin disodium, which contains 5.2 mEq of sodium per gram of drug) along with avoiding dehydration appears to be a safe and effective means of reducing the risk of nephrotoxicity associated with amphotericin B administration; however, it is not known whether renal changes can be entirely prevented. These preliminary observations merit confirmation in a prospective, randomized clinical trial. (Arch Intern Med1988;148:2389-2394) The incidence of mycotic disease is increasing. A recent survey indicates that fungal organisms are isolated in from 1% to 12% of hospitalized patients, currently accounting for approximately 5% of all cases of primary septicemia.1The reason for this escalation in mycotic disease is the increased number of patients occupying hospital beds with risk factors for fungal infections. The major risk factor is impaired host defense mechanisms due to underlying disease (eg, acquired immunodeficiency syndrome) or therapeutic maneuvers (eg, cancer chemotherapy, radiotherapy, iatrogenic immunosuppression for organ transplantation). Despite the availability of newer antifungal agents, amphotericin B (Fungizone) remains the broad-spectrum antifungal antibiotic of choice for the treatment of deepseated mycotic infections. Unfortunately, this drug causes a variety of adverse effects, including fever, chills, nausea,
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,009
KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury
Palevsky, P. M., Liu, K. D., Brophy, P. D., Chawla, L. S., Parikh, C. R., Thakar, C. V., Tolwani, A. J., Waikar, S. S., & Weisbord, S. D. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.02.349 · Cited by 935
Wingard, J. R., White, M. H., Anaissie, E., Raffalli, J., Goodman, J., Arrieta, A., & L Amph/ABLC Collaborative Study Group (2000) · Clinical Infectious Diseases · doi:10.1086/317451 · Cited by 527
Clinical and laboratory update on blastomycosis.
Saccente, M., & Woods, G. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00056-09 · Cited by 450
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Metadata
- Authors
- Branch, R. A.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 1988-11-01
- Volume
- 148
- Issue
- 11
- Pages
- 2389
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2118969464
- Cited by
- 194
- References
- 0
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention of Amphotericin B—Induced Renal Impairment: A Review on the Use of Sodium Supplementation. https://app.cochat.ai/papers/10.1001/archinte.1988.00380110049010
- The paper
- Branch, R. A. (1988). Prevention of Amphotericin B—Induced Renal Impairment: A Review on the Use of Sodium Supplementation. Archives of Internal Medicine. https://doi.org/10.1001/archinte.1988.00380110049010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.